S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
LON:AGL

ANGLE - AGL Price Target & Analyst Ratings

GBX 67.50
-0.30 (-0.44%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
67.30
70
50-Day Range
62.96
78
52-Week Range
61
163.75
Volume
470,502 shs
Average Volume
840,787 shs
Market Capitalization
£175.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 231

ANGLE Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

GBX 231
High PredictionGBX 231
Average PredictionGBX 231
Low PredictionGBX 231
TypeCurrent
10/5/21 to 10/5/22
1 Month Ago
9/5/21 to 9/5/22
3 Months Ago
7/7/21 to 7/7/22
1 Year Ago
10/5/20 to 10/5/21
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetGBX 231GBX 231GBX 195N/A
Get ANGLE Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.


AGL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ANGLE Stock vs. The Competition

TypeANGLEMedical Companies
Consensus Rating Score
3.00
2.68
Consensus RatingBuyBuy
News Sentiment RatingPositive News
Positive News
MarketBeat
Community Rating
Outperform Votes
177
61.67%
Underperform Votes
110
38.33%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/5/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 231+227.43%
7/20/2020FinnCap
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingCorporate
(Data available from 10/5/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AGL Price Target - Frequently Asked Questions

What is ANGLE's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for ANGLE stock is Buy based on the current 1 buy rating for AGL. The average twelve-month price prediction for ANGLE is GBX 231 with a high price target of GBX 231 and a low price target of GBX 231. Learn more on AGL's analyst rating history.

Do Wall Street analysts like ANGLE more than its competitors?

Analysts like ANGLE more than other Medical companies. The consensus rating score for ANGLE is 3.00 while the average consensus rating score for medical companies is 2.68. Learn more on how AGL compares to other companies.

Do MarketBeat users like ANGLE more than its competitors?

MarketBeat users like ANGLE less than other Medical companies. 61.67% of MarketBeat users gave ANGLE an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does ANGLE's stock price have much upside?

According to analysts, ANGLE's stock has a predicted upside of 227.43% based on their 12-month price targets.

What analysts cover ANGLE?

ANGLE has been rated by Berenberg Bank in the past 90 days.


Stock Ratings Reports and Tools

This page (LON:AGL) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.